AbbVie

Thumbnail for AbbVie partners with Neomorph to develop novel degrader therapies

27 January 2025

AbbVie partners with Neomorph to develop novel degrader therapies

Thumbnail for European Commission approves AbbVie’s Elahere for platinum-resistant ovarian cancer

20 November 2024

European Commission approves AbbVie’s Elahere for platinum-resistant ovarian cancer

Thumbnail for AbbVie partners with EvolveImmune to develop Next-Generation cancer treatments

5 November 2024

AbbVie partners with EvolveImmune to develop Next-Generation cancer treatments

Thumbnail for AbbVie acquires Aliada Therapeutics for US$1.4B to accelerate Alzheimer’s research

29 October 2024

AbbVie acquires Aliada Therapeutics for US$1.4B to accelerate Alzheimer’s research

Thumbnail for AbbVie submits lung cancer drug Teliso-V for FDA approval

2 October 2024

AbbVie submits lung cancer drug Teliso-V for FDA approval

Thumbnail for AbbVie’s Elahere gets positive CHMP opinion for ovarian cancer treatment

23 September 2024

AbbVie’s Elahere gets positive CHMP opinion for ovarian cancer treatment

Thumbnail for AbbVie’s TEPKINLY approved for follicular lymphoma

20 August 2024

AbbVie’s TEPKINLY approved for follicular lymphoma

Thumbnail for European Commission approves AbbVie’s SKYRIZI for Ulcerative Colitis Treatment

1 August 2024

European Commission approves AbbVie’s SKYRIZI for Ulcerative Colitis Treatment

Thumbnail for AbbVie bolsters IBD portfolio with US$250M acquisition of Celsius Therapeutics

28 June 2024

AbbVie bolsters IBD portfolio with US$250M acquisition of Celsius Therapeutics

Thumbnail for AbbVie’s EPKINLY gains FDA approval for relapsed follicular lymphoma

27 June 2024

AbbVie’s EPKINLY gains FDA approval for relapsed follicular lymphoma